Wulf O. Boecher

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study

Johannes Wiegand, Peter Buggisch, Wulf O. Boecher et al. · Hepatology · 2006 · 252 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?

Elke Hennes, Ye Htun Oo, Christoph Schramm et al. · The American Journal of Gastroenterology · 2008 · 189 citations

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

Stefan Zeuzem, Tarik Asselah, Peter Angus et al. · Gastroenterology · 2011 · 134 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

Michael P. Manns, Marc Bourlière, Yves Benhamou et al. · Journal of Hepatology · 2010 · 112 citations

Medicine, Pharmacokinetics, Pharmacology +14

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection

Andrej Potthoff, Heiner Wedemeyer, Wulf O. Boecher et al. · Journal of Hepatology · 2008 · 93 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16